{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:59:30Z","timestamp":1775818770027,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The Department of Clinical Cancer Genetics at the Institute of Oncology Ljubljana offers genetic counselling and testing to cancer patients and their relatives. Before undergoing genetic testing, patients sign the informed consent form. In addition to giving consent for collection of biological material and genetic testing, patients decide about storage of biological material and participation in international databases. Furthermore, patients decide whether the information regarding their test results may be revealed to their blood relatives and whether they want to be informed about secondary findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using the signed consent forms, we investigated the effect of selected factors on patients\u2019 decisions. Using different statistical methods, we tried to determine the proportion of patients who opted for different items and the effect of gender, age and cancer diagnoses on their decisions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Nearly all (99.6%) patients, regardless of gender, age, and presence of oncological diagnosis, consented to the storage of their biological material, 98.4% of patients, regardless of gender, age, and presence of oncological diagnosis, wanted to be included in international databases in a pseudo-anonymised form, 98.8% of patients, irrespective of gender, age, and presence of oncological diagnosis, allowed blood relatives to see their results, and 98.4% of patients, irrespective of gender, age and presence of oncological diagnosis, wanted to know whether secondary findings were detected when genetic analysis of their biological material was performed. Men are, on average, more likely to consent but the difference between genders is not statistically significant. Patients without oncological disease were more likely to agree to be included in international databases than patients with a confirmed oncological diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our results show that the vast majority of patients were in favour of the options they were offered. Most importantly, the majority of them allow their genetic test results be revealed to their blood relatives when needed and would participate in international databases. Research in rare diseases, including rare cancer genetic predisposition syndromes, is crucial for optimal diagnostic, prevention and treatment options for patients with rare genetic disorders. The results are also important for refining the approach to pre-and post-test cancer genetic counselling.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13053-025-00309-8","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:37:20Z","timestamp":1740130640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of informed consent forms of patients undergoing cancer genetic testing in the era of next-generation sequencing"],"prefix":"10.1186","volume":"23","author":[{"given":"Tina","family":"Ker\u0161evan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Kogov\u0161ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Blatnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-2592","authenticated-orcid":false,"given":"Mateja","family":"Krajc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"2","key":"309_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/aps.2015.89","volume":"37","author":"Q Wang","year":"2016","unstructured":"Wang Q. Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes. Acta Pharmacol Sin. 2016;37(2):143\u20139. https:\/\/doi.org\/10.1038\/aps.2015.89. Epub 2015 Nov 30. PMID: 26616728; PMCID: PMC4753377.","journal-title":"Acta Pharmacol Sin"},{"key":"309_CR2","doi-asserted-by":"publisher","unstructured":"Panoyan L, Lee S, Arar R, Abbound HE, Arar N. The informed consent process in genetic Family studies. Life Sci Soc Policy 2008 Avg 15;4(2):11\u201320. https:\/\/doi.org\/10.1186\/1746-5354-4-2-11","DOI":"10.1186\/1746-5354-4-2-11"},{"issue":"11","key":"309_CR3","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1002\/ajmg.a.37256","volume":"167A","author":"BA Bernhardt","year":"2015","unstructured":"Bernhardt BA, Roche MI, Perry DL, Scollon SR, Tomlinson AN, Skinner D. Experiences with obtaining informed consent for genomic sequencing. Am J Med Genet A. 2015;167A(11):2635\u201346. https:\/\/doi.org\/10.1002\/ajmg.a.37256.","journal-title":"Am J Med Genet A"},{"key":"309_CR4","unstructured":"U.S. National Library of Medicine. Help Me Understand Genetics by MedlinePlus. [Accessed 10th September 2020] Available from: https:\/\/medlineplus.gov\/genetics\/"},{"key":"309_CR5","unstructured":"Zakon o pacientovih pravicah (ZPacP). (2008, 2017, 2020, 2022). Uradni list RS, (15\/08, 55\/17, 177\/20 in 100\/22)."},{"issue":"1","key":"309_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s10897-017-0127-2","volume":"27","author":"SA Fowler","year":"2018","unstructured":"Fowler SA, Saunders CJ, Hoffman MA. Variation among consent forms for clinical whole exome sequencing. J Genet Couns. 2018;27(1):104\u201314. https:\/\/doi.org\/10.1007\/s10897-017-0127-2.","journal-title":"J Genet Couns"},{"key":"309_CR7","doi-asserted-by":"publisher","unstructured":"Samuel GN, Dheensa S, Farsides B, Fenwick A, Lucassen A. Healthcare professionals\u2019 and patients\u2019 perspectives on consent to clinical genetic testing: moving towards a more relational approach. BMC Med Ethics. 2017;18(47). https:\/\/doi.org\/10.1186\/s12910-017-0207-8.","DOI":"10.1186\/s12910-017-0207-8"},{"key":"309_CR8","unstructured":"Krajc M, Blatnik A, Ker\u0161evan T, Hotujec S. (2020). Klini\u010dna pot obravnave pacienta v Ambulanti za onkolo\u0161ko genetsko svetovanje in testiranje. Institute of Oncology Ljubljana. [Accessed 1th September 2024] Available from: https:\/\/www.onko-i.si\/fileadmin\/onko\/datoteke\/Strokovna_knjiznica\/klinicne_poti\/Klinicna_pot_obravnave_pacienta_v_Ambulanti_za_onkolosko_genetsko_svetovanje_in_testiranje_2020.pdf"},{"key":"309_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12885-019-5535-2","volume":"19","author":"A Gornjec","year":"2019","unstructured":"Gornjec A, Novakovic S, Stegel V, Hocevar M, Pohar Marinsek Z, Gazic B, Krajc M, Skof E. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1\/2 genes in patients with tubo-ovarian high grade serous carcinoma. BMC Cancer. 2019;19:296.","journal-title":"BMC Cancer"},{"key":"309_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/genes11030325","volume":"11","author":"G Klan\u010dar","year":"2020","unstructured":"Klan\u010dar G, Blatnik A, \u0160etraj\u010di\u010d Drago\u0161 V, Vogri\u010d V, Stegel V, Blatnik O, Drev P, Gazi\u010d B, Krajc M, Novakovi\u0107 S. A novel germline MLH1 In-Frame deletion in a Slovenian Lynch Syndrome Family Associated with Uncommon isolated PMS2 loss in Tumor tissue. Genes. 2020;11:325.","journal-title":"Genes"},{"issue":"8","key":"309_CR11","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41436-021-01171-4","volume":"23","author":"DT Miller","year":"2021","unstructured":"Miller DT, Lee K, Gordon AS, Amendola LM, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Sci. 2021;23(8):1391\u20138. https:\/\/doi.org\/10.1038\/s41436-021-01171-4.","journal-title":"Genet Sci"},{"key":"309_CR12","doi-asserted-by":"publisher","unstructured":"Miller DT, Lee K, Abul-Husn NS, Amendola LM, Brothers K, Chung WK, Gollob MH, Gordon AS, Harrison SM, Hershberger RE, Klein TE, Richards CS, Stewart DR, Martin CL, ACMG Secondary Findings Working Group. (2022). ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in medicine. 2022;24(7): 1407\u20131414. https:\/\/doi.org\/10.1016\/j.gim.2022.04.006","DOI":"10.1016\/j.gim.2022.04.006"},{"key":"309_CR13","doi-asserted-by":"publisher","unstructured":"Ivashkov Y, Van Norman GA. Informed consent and the ethical management of the older patient. Anesthesiol Clin. 2009;27(3):569\u2013\u200980. https:\/\/doi.org\/10.1016\/j.anclin.2009.07.016. PMID: 19825493.","DOI":"10.1016\/j.anclin.2009.07.016"},{"key":"309_CR14","doi-asserted-by":"publisher","unstructured":"Tekola F, Bull SJ, Farsides B, Newport MJ, Adeyemo A, Rotimi CN et al. (2009) Tailoring Consent to Context: Designing an Appropriate Consent Process for a Biomedical Study in a Low Income Setting. PooS Negl Trop Dis. 2009;3(7):e482. https:\/\/doi.org\/10.1371\/journal.pntd.0000482","DOI":"10.1371\/journal.pntd.0000482"},{"issue":"11","key":"309_CR15","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.2105\/AJPH.2005.076232","volume":"96","author":"PA Marshall","year":"2006","unstructured":"Marshall PA, Adebamowo CA, Adeyemo AA, Ogundiran TO, Vekich M, Strenski T, Zhou J, Prewitt TE, Cooper RS, Rotimi CN. Voluntary participation and informed consent to international genetic research. Am J Public Health. 2006;96(11):1989\u201395. https:\/\/doi.org\/10.2105\/AJPH.2005.076232.","journal-title":"Am J Public Health"},{"key":"309_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ejca.2021.02.029","volume":"148","author":"EM Bunnik","year":"2021","unstructured":"Bunnik EM, Dondorp WJ, Bredenoord AL, de Wert G, Cornel MC. Mainstreaming informed consent for genomic sequencing: a call for action. Eur J Cancer. 2021;148:405\u201310. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.029.","journal-title":"Eur J Cancer"},{"key":"309_CR17","unstructured":"General Data Protection Regulation. Regulation (EU) 2016\/679 of the European parliament and of the Council of the European union. [Accessed 5th May 2021]. Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32016R0679%26;from=EN"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-025-00309-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-025-00309-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-025-00309-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:37:24Z","timestamp":1740130644000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-025-00309-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["309"],"URL":"https:\/\/doi.org\/10.1186\/s13053-025-00309-8","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee of the Institute of Oncology Ljubljana, the Institutional Review Board of the Institute of Oncology Ljubljana (KSOPKR (ERIDNPVO\/-0025\/2020)) and the National Medical Ethics Committee of the Republic of Slovenia. Research was conducted according to the 1975 Helsinki Declaration as revised in 2013.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval >and concent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}